Tiziana Life Sciences Plc

204 articles about Tiziana Life Sciences Plc

• Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

  11/1/2023

  Tiziana Life Sciences Ltd.  today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023.

• Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

  10/11/2023

  Tiziana Life Sciences Ltd. announced a late breaking poster titled, “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody : Safety, Biomarker, And Disability Outcomes”, will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis being held in Milan, Italy, October 11-13, 2023.

• Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

  9/26/2023

  Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients.

• Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/8/2023

  Tiziana Life Sciences Ltd.  today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.

• Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

  8/23/2023

  Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.

• Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

  8/17/2023

  Tiziana Life Sciences Ltd. today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on Bloomberg to discuss the Company’s latest announcement on its advancement of the novel foralumab program in Alzheimer's disease following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance.

• Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

  8/15/2023

  Tiziana Life Sciences Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease.

• Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice - July 21, 2023

  7/21/2023

  Tiziana Life Sciences disclosed the receipt of a notice on July 19, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company’s common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450.

• Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer

  6/13/2023

  Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer.

• Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

  6/5/2023

  Tiziana Life Sciences Ltd. announced a reduction in microglial activation as seen in 3-month Positron Emission Tomography scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis treated with intranasal foralumab in its Expanded Access program.

• Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform

  5/23/2023

  Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, announced that they are now participating on the new Webull Corporate Communication services platform.

• Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

  5/17/2023

  Tiziana Life Sciences Ltd. today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego.

• Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

  4/27/2023

  Tiziana Life Sciences Ltd. today announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference.

• Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

  4/26/2023

  Tiziana Life Sciences, Ltd. announced financial results for the twelve months ended December 31, 2022, and provided a corporate update on its lead programs in development.

• Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

  4/24/2023

  Tiziana Life Sciences Ltd. today announces that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

• Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

  4/20/2023

  Tiziana Life Sciences Ltd. today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.

• Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

  4/18/2023

  Tiziana Life Sciences Ltd. announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes.

• Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

  4/13/2023

  Tiziana Life Sciences Ltd. today announced it plans to investigate intranasal foralumab for the treatment of Long COVID.

• Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

  4/10/2023

  Tiziana Life Sciences Ltd. today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientific conference and exhibit held at the Fondazione Prada in Rong Zhai in Shanghai.

• Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

  4/4/2023

  Tiziana Life Sciences Ltd. today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American Academy of Neurology (AAN) conference in Boston, MA.